Centrient Pharmaceuticals, producer and supplier of sustainable antibiotics, statins and anti-fungals, has announced the appointment of Dr Manja Boerman as a Non-Executive Director, effective from September 1, 2021.
Benjamin Kunstler, MD Healthcare Vertical at Bain Capital Private Equity and Chairman of the Centrient Supervisory Board, commented: “We are pleased to welcome Manja Boerman to the Supervisory Board. In the past two decades, she fulfilled various President and Chief Executive Officer roles within biopharmaceutical and pharmaceutical contract development and manufacturing organizations, and biotech companies. With her background and experience, she will bring diverse perspectives and is optimally suited to advise Centrient in the next phase of its growth trajectory.”
Rex Clements, CEO at Centrient, added: “Manja Boerman’s extensive experience will be invaluable to Centrient Pharmaceuticals as we continue to grow our company. We look forward to the business insights she will bring to the Supervisory Board.”
“It’s a pleasure to join a company with a strong sense of purpose coupled with such a dedicated, experienced leadership team,” said Manja Boerman. “I look forward to collaborating with the members of the Centrient Pharmaceuticals Supervisory Board as well as sharing my experience and learnings.”
Boerman is the President of Catalent Cell & Gene Therapy with overall responsibility for strategy and leadership of the cell and gene businesses. She has more than 20 years’ experience in biotech and pharmaceutical services, and significant experience in start-up environments and global late-stage clinical development for cell therapy products.
She has held several executive leadership positions at previous companies including President of Aesica Pharmaceuticals, President of Patheon Biologics, President of DSM Biologics and she served as CEO of biotech companies Kiadis Pharma and Regenesance. Boerman holds a PhD in Biochemistry from the State University of New York.